WO2009013357A1 - Utilisation d'écorces de levure pour le traitement et / ou la prévention de l'hyperinsulinémie - Google Patents
Utilisation d'écorces de levure pour le traitement et / ou la prévention de l'hyperinsulinémie Download PDFInfo
- Publication number
- WO2009013357A1 WO2009013357A1 PCT/EP2008/059815 EP2008059815W WO2009013357A1 WO 2009013357 A1 WO2009013357 A1 WO 2009013357A1 EP 2008059815 W EP2008059815 W EP 2008059815W WO 2009013357 A1 WO2009013357 A1 WO 2009013357A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- yeast
- mass
- solids
- less
- hyperinsulinemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- yeast peels for the treatment and / or prevention of hyperinsulinemia
- the present invention relates to the use of yeast peels for the treatment and / or prevention of hyperinsulinemia.
- Insulin is a hypoglycemic hormone secreted by the ⁇ -cells of islets of Langerhans of the pancreas. Insulin can lower blood glucose, particularly by activating glucose transport in target tissues (muscle, liver and fat tissue).
- Type 2 diabetes is characterized by insulin-resistance resulting in a first phase by hyperinsulinism. Some obesities are also associated with hyperinsulinism. In the case of diabetes with insulin resistance, drugs that reduce excess blood sugar without stimulating insulin secretion may be prescribed (eg metformin).
- JP-A-61-167622 discloses a diabetes control agent based on a cell fraction of brewery yeast called cell wall in this document and obtained by hydrolysis of deaminated brewer's yeast for at least 2 hours at a time. temperature of 50 to 70 0 C and aqueous extraction of the constituents soluble in water.
- Said cell fraction of brewery yeast has in particular a glucan content of about 14.8%, a mannan content of about 13.9%.
- Said cell fraction also has a glycogen content of about 24.9%.
- Glycogen is a reserve polysaccharide that is also present in the muscles and especially in the liver. This glycogen is also a yeast reserve substance, used by the yeast as a source of energy to ensure its survival. While it is one of the main components of the cell fraction described in this Japanese application, it is not part of the yeast cell wall.
- Patent application WO2005 / 021015 describes the use of yeast peels for the prevention and treatment of hyperglycemia and for the stabilization of blood glucose, said yeast peels having a low glycogen content and obtainable by a method of autolysis or simple enzymatic hydrolysis.
- the total content of glucans and mannan in said yeast peels is at least 34.0% by mass on solids.
- the ⁇ -glucans in the cell wall of yeast are essentially glucose polymers whose glucose units in the main chain are linked by ⁇ -1,3 bonds and whose branches are linked by ⁇ -1,6 bonds.
- Yeast ⁇ -glucans are insoluble and have a low viscosity.
- ⁇ -glucans purified from the cell wall of yeast have immunostimulatory properties. In particular, it has been shown that yeast ⁇ -glucans are able to bind to macrophages and activate them.
- yeast ⁇ -glucans are studied for antibacterial, antiviral and antitumor applications (Adams D.S., Journal of Leukocyte Biology, 1997).
- the subject of the present invention is the use of yeast peels as an insulin-regulating agent.
- An object of the invention is in particular the use of yeast peels in the treatment and / or prevention of hyperinsulinemia.
- the present invention relates to the use of yeast peels for the preparation of a pharmaceutical composition for the treatment and / or prevention of hyperinsulinemia, said yeast peels having:
- yeast bark refers to the insoluble fraction of yeast cells, not chromium enriched, obtained after autolysis or enzymatic hydrolysis, essentially by proteases, leading to solubilization of at least 50% and preferably at least 60% by weight of the dry materials of whole yeast cells and retaining the polysaccharides of cell wall structure, that is to say ⁇ -glucans and mannan, these mannans being in the form of mannoproteins.
- This autolysis or enzymatic hydrolysis is conducted so as to solubilize most of the yeast cell reserve sugars glycogen and trehalose.
- the yeast peels are obtained by separating the solubilized fraction by autolysis or enzymatic hydrolysis, the latter having a duration preferably of at least 18 hours.
- autolysis yeast creams are described on pages 370-377 in the reference work "Yeast Technology", 2nd edition, 1991, G. Reed and TW Nogodawithana, published by Van Nostrand Reinhold, New York, ISBN 0-442-31892-8.
- the yeast hulls thus obtained are then typically dried by a conventional drying process, such as spray drying or heated roll drying.
- the yeast peels according to the invention have a total content of glucans and mannan cell wall (systematically expressed in equivalent weight of respectively glucose and mannose - see measurement methods below) of at least 34.0% by weight on dry matter, as well as a glycogen content (systematically expressed as an equivalent weight of glucose - see measurement methods below) of less than 10.0% by mass on dry matter.
- hypoinsulinemia is meant both basal hyperinsulinemia and postprandial hyperinsulinemia.
- the yeast peels according to the invention are used for the prevention and / or treatment of post-prandial hyperinsulinemia.
- the yeast peels according to the invention are used for the prevention and / or treatment of basal hyperinsulinemia.
- the yeast peels according to the invention are used for the prevention and / or treatment of both basal hyperinsulinemia and postprandial hyperinsulinemia.
- Basal hyperinsulinemia is characterized by a basal plasma concentration of high insulin.
- the basal level corresponds to insulin concentrations outside food intake, especially when the subject is fasting.
- the physiological basal level is generally less than or equal to 10 mU / 1 in healthy thin subjects.
- a basal hyperinsulinemia can be characterized by a basal level, outside food intake (especially fasting), greater than 10 mU / 1.
- Postprandial hyperinsulinemia corresponds to an insulin response excessive following ingestion of food.
- Postprandial hyperinsulinemia can be demonstrated by an oral glucose tolerance test (OGTT).
- OGTT oral glucose tolerance test
- the physiological response to the OGTT test is characterized by a peak of insulin secretion generally between 30 and 60 mU / L in the healthy thin subject.
- post-prandial hyperinsulinemia may be characterized by a response to the OGTT test with a peak insulin secretion greater than 60 mU / L.
- the plasma insulin concentration of a patient is measured by conventional techniques well known to those skilled in the art.
- an RIA test Radiolmmuno-Assay
- a plasma sample of a patient for example RIA, Biosource, Medgenix Diagnostics, Rungis, France.
- Treatment of hyperinsulinemia is intended to lower the basal plasma concentration of insulin and / or restore a physiological insulin response following ingestion of food.
- the prevention of hyperinsulinemia is intended to maintain the basal plasma insulin concentration at physiological values and / or to maintain a physiological insulin response following ingestion of food.
- the present invention particularly relates to the treatment and / or prevention of postprandial hyperinsulinemia.
- the present invention particularly relates to the use as defined above, in which the yeast peels are of the genus Saccharomyces cerevisiae.
- Said yeasts are preferably baker's yeasts.
- a baker's yeast is a yeast belonging to the species Saccharomyces cerevisiae, manufactured using essentially a multiplication or aerobic culture as taught in the reference work "Yeast Technology" cited above and having served before its autolysis or enzymatic hydrolysis to no use, unlike, for example, brewer's yeast which is a by-product of the manufacture of beer and which has therefore been used to make beer before its recovery for its autolysis or hydrolysis enzyme. This brewery yeast has been multiplied mainly in anaerobic (the manufacture of beer is an anaerobic process).
- yeast peels have a total content of glucans and mannans of at least 40.0% by mass on solids, preferably at least 45%, 0% by mass on dry matter.
- Useful yeast barks according to the invention have a protein content Nx6.25 of 17.0 to 35.0% by mass on solids, preferably 18.0 to 26.0% by mass on materials dry.
- the invention particularly relates to the use as defined above, wherein said yeast peels have a mannan content of less than 30% by mass on solids.
- the mannan content in the yeast bark is from 20 to 26% by weight on solids.
- This embodiment corresponds to yeast hulls obtained by autolysis or enzymatic hydrolysis, separation of the solubilized fraction, and drying of the nonsoluble fraction as described previously and in Example 1.1 (part entitled Preparation of yeast peels containing mannans).
- Such a product makes it possible to obtain, after an orally induced hyperglycemia test (OGTT), a decreased insulin peak compared to a placebo in patients suffering from type 2 diabetes (see Example 2).
- OGTT orally induced hyperglycemia test
- the subject of the present invention is in particular the use as defined above, in which said yeast peels have a mannan content of less than 2% by mass on dry matter, in particular less than 1% by mass on dry matter, in particular less than 0.1% by mass on solids.
- the mannan content of the yeast peels is less than 0.1% by weight on solids.
- Mannans can be removed by hot alkaline treatment.
- the hot alkaline treatment consists in suspending the aqueous yeast barks according to the invention obtained as described above and heating the suspension in an alkaline medium between 70 0 C and 100 0 C for up to three hours.
- the fraction solubilized by this treatment containing a large part or even all of the mannoproteins is removed by centrifugation and washing.
- the unsolubilized fraction remaining is recovered and usually dried.
- the mannans are removed by hot alkaline treatment followed by acid treatment, in order to completely eliminate mannan.
- Such products obtained from the yeasts of previous yeasts subjected to a hot alkaline treatment and possibly to an acid treatment, as described previously (see also Example 1.1 part entitled Preparations of yeast peels devoid of mannans), and in which mannan have been eliminated in whole or in part (glucans account for the bulk of the total glucan and mannan content), allow to obtain after a test OGTT insulin peak decreased compared to a placebo, and even compared to the barks yeasts in which the mannans have not been eliminated, in patients suffering from type 2 diabetes or overweight (see Example 2).
- the subject of the present invention is the use as defined above, in which the yeast peels have a total glucan and mannan content of less than or equal to 90% by mass on solids, in particular less than or equal to 80% by weight. mass on dry matter, especially less than or equal to 70% by mass on dry matter.
- the present invention more particularly relates to the use as defined above, in which the yeast peels have a total content of glucans and mannan from 45% to 90% by mass on dry matter, in particular
- the content of glucans and mannan is from 72% to 77% by mass on dry matter.
- the subject of the present invention is the use as defined above, in which the content of glucans and mannans is from 72% to 77% by mass on solids and the content of mannan is less than 2% by mass on dry matter, in particular less than 1% by mass on dry matter, in particular less than 0.1%.
- the glucan and mannan content may also be lower or equal to 55% by mass on dry matter, as long as it remains greater than 45% by mass on dry matter.
- the glucan and mannan content is from 52% to 57% by weight on solids.
- the subject of the present invention is the use as defined above, in which the content of glucans and mannans is from 52% to 57% by mass on solids and the content of mannan is less than 2% by mass on dry matter, in particular less than 1% by mass on dry matter, in particular less than 0.1%.
- the subject of the present invention is the use as defined above, in which the yeast peels have a glycogen content of less than 8.0% by mass on solids, preferably less than 5.0% by weight on dry matter, preferably less than 3.0% by weight on solids, preferably less than 1.0% by weight on solids, more preferably less than 0.1% by weight on solids.
- the yeast peels according to the invention may be subjected to an alkaline treatment under heat, as described above, and preferably to an alkaline treatment with hot followed by acid treatment.
- a treatment makes it possible to produce yeast peels according to the invention having a total content of glucans and mannans of from 45% to 90% by mass on solids, preferably from 52% to 80% by mass on solids, preferably from 65% to 77% by weight and still preferably 72 to 77% by mass on dry matter.
- Such a treatment makes it possible in particular to produce yeast peels which also contain less than 1.0% by weight of glycogen on solids, preferably less than 0.1% by weight of glycogen on solids.
- composition according to the invention can be administered in various forms or presentations.
- the pharmaceutical composition according to the invention comprises at least one active substance represented by yeast peels and a pharmaceutically acceptable vehicle.
- the pharmaceutical composition according to the invention may comprise one or more other active substances, for example chosen from hypoglycemic or insulin-sensitizing agents, and especially from the hypoglycemic sulfonylureas, biguanide, metformin and thiazolidinedione derivatives, ⁇ -glucosidase inhibitors.
- the preparation may also comprise one or more vitamins, chosen in particular from vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, vitamins B1 (thiamine), B2 (riboflavin), B3 (niacin), B5 (pantothenic acid) , B6, B8 (biotin), B9 (folic acid), B12 (cobolamine) and / or one or more dietary minerals, especially selected from calcium, phosphorus, potassium, sodium, magnesium and iron.
- the present invention also relates to pharmaceutical compositions as defined above comprising chromium.
- the pharmaceutical composition may comprise one or more pharmaceutically acceptable excipients.
- the pharmaceutical composition according to the invention is suitable for oral administration.
- the pharmaceutical composition may especially be in the form of a tablet, capsule, pill, powder, granules or suspension.
- the pharmaceutical composition according to the invention may in particular be in the form of an ingestion dose corresponding to an amount of yeast bark dry matter according to the invention of less than 10 g, preferably 8 to 9 g.
- the subject of the present invention is the use as defined above, in which the yeast peels have a solids content greater than or equal to 90%, preferably greater than or equal to 94%. and still preferably greater than or equal to 96% by weight.
- a solids content greater than or equal to 90%, especially greater than or equal to 94%, more preferably greater than or equal to 96%, allows better preservation of yeast peels, in particular better bacteriological stability and better stability vis-à-vis -vis of adverse reactions of origin enzymatic or not.
- the subject of the present invention is the use of yeast peels as defined above for the prevention and / or treatment of hyperinsulinemia, whether it be basal or postprandial hyperinsulinemia, whatever either the origin of hyperinsulinemia.
- the present invention particularly relates to the use of yeast peels as defined above for the prevention and / or treatment of hyperinsulinemia associated with insulin resistance, overweight, obesity, or metabolic syndrome, in any type of patient suffering from hyperinsulinemia of this origin.
- the barks according to the invention are used for the preparation of a medicament for the prevention and / or treatment of hyperinsulinemia in a non-diabetic patient.
- the subject of the present invention is particularly the use of yeast peels as defined above for the prevention and / or treatment of hyperinsulinemia associated with insulin resistance, overweight, obesity, or metabolic syndrome, always in non-diabetic subjects.
- the barks according to the invention can also be used for the preparation of a medicament for the prevention and / or treatment of hyperinsulinemia in a type-2 diabetic patient.
- the present invention therefore has the particular object of use of yeast peels as defined above for the prevention and / or treatment of hyperinsulinemia associated with insulin resistance, overweight, obesity, or metabolic syndrome, in a diabetic subject of type 2.
- Type 2 diabetes also refers to non-insulin-dependent diabetes mellitus (NIDDM).
- Type 2 diabetes is characterized by fasting blood glucose greater than 1.26 g / L. When fasting glucose is between 1.10 g / L and 1.26 g / L, it is called abnormal blood glucose.
- the present invention particularly relates to the use of yeast peels as defined above for the prevention and / or treatment of hyperinsulinemia in the early stages of type 2 diabetes.
- Insulin-resistance refers to the lack of response of insulin-dependent tissues to the action of insulin. The pancreas then continues to secrete insulin whose plasma concentration becomes too high.
- overweight is characterized by a Body Mass Index (BMI) of 25 to 30 kg / m 2 and obesity by a Body Mass Index (BMI) of over 30 kg / m 2 .
- BMI Body Mass Index
- the Body Mass Index of an individual is defined by the following formula:
- weight or obesity in non-diabetic subjects means overweight or obesity as defined above in subjects whose blood glucose is properly regulated.
- the plasma glucose concentration of fasting non-diabetic subjects is less than 1.26 g / L (7 mmol / L), especially less than 1.10 g / L to (6.1 mmol / L).
- metabolic syndrome is used to refer to a set of risk factors for the development of cardiovascular disorders, strokes and type 2 diabetes.
- the diagnosis of the metabolic syndrome is based on the evaluation of several parameters, including waist circumference, cholesterol and triglyceride concentration, fasting blood glucose, insulinemia and blood pressure.
- the metabolic syndrome is diagnosed if three or more of the following risk factors are present:
- Post-prandial hyperinsulinemia may play a role in the development of the metabolic syndrome.
- the present invention also relates to a method for the treatment and / or prevention of hyperinsulinemia in a patient, comprising administering to the patient a pharmaceutical composition according to the invention.
- the method for the treatment and / or prevention of hyperinsulinemia may in particular be a method for the treatment and / or prevention of hyperinsulinemia associated with insulin resistance, overweight, obesity, or metabolic syndrome.
- the patient is a non-diabetic patient.
- the patient may also be a type 2 diabetic patient.
- the invention particularly relates to such a method wherein the pharmaceutical composition is administered to the patient orally.
- the various methods according to the invention may in particular comprise the administration to the patient of the pharmaceutical composition in a daily dose corresponding to 1 to 10 g, preferably 8 to 9 g of yeast peels according to the invention, said dose daily can be administered in a single dose or a single time of administration, such as breakfast, or in several partial doses, that is to say, spread over the day.
- the methods according to the invention may also comprise at least one step of verifying the basal insulin concentration of the patient and / or his insulin response following the ingestion of food or an OGTT test, after the administration of the pharmaceutical composition in acute or chronic.
- the methods according to the invention may further comprise a step of measuring the basal insulin concentration of the patient and / or evaluation of his insulin response following the ingestion of food or an OGTT test, prior to administration. of the pharmaceutical composition above in acute or chronic.
- the present invention also relates to a method for decreasing or stabilizing basal plasma insulin concentration in a patient suffering from basal hyperinsulinemia, comprising administering to said patient an effective amount of a pharmaceutical composition according to the invention.
- the method for decreasing or stabilizing the basal plasma concentration of insulin may in particular target a patient suffering from basal hyperinsulinemia associated with insulin resistance, overweight, obesity, or metabolic syndrome.
- the patient is a non-diabetic patient.
- the patient may also be a type 2 diabetic patient.
- the present invention also relates to a method for decreasing the peak of insulin secretion following ingestion of food in a patient suffering from postprandial hyperinsulinemia, comprising administering to said patient an effective amount of a pharmaceutical composition according to the invention.
- the method for decreasing insulin secretion peak following ingestion of food may in particular target a patient with postprandial hyperinsulinemia associated with insulin resistance, overweight, obesity, or metabolic syndrome.
- the patient is a non-diabetic patient.
- the patient may also be a type 2 diabetic diabetic patient.
- the insulin concentration (in mU / l) is given as a function of time in minutes (min).
- the results of 3 days of exploration are given on average +/- ESM.
- the area under curve obtained in the control subjects having ingested milk is black, in the subjects having ingested yeast peels devoid of tightly dotted mannans (betaglucans) and in the subjects having ingested the yeast peels with dotted mannans. cowards.
- the area of insulinemia (in mU / l * time) is given for the period 0-300 minutes (early), the period 0-120 minutes and the period 120-300 minutes.
- the results of 3 days of exploration are given on average +/- ESM.
- the insulinemia of control subjects who had ingested milk appeared in a solid line and squared, subjects ingested yeast peels devoid of mannan (betaglucans) in dashes and lozenges, and subjects having ingested yeast peel with dotted mannan and triangles.
- the insulin concentration (in mU / l) is given as a function of time in minutes (min).
- the area of insulinemia (in mU / l * time) is given for the period 0-300 minutes (early), the period 0-120 minutes and the period 120-300 minutes.
- aqueous cream i.e. a suspension of yeast cells in water
- Sacharomyces cerevisiae having a solids content between 12 and 18% by weight
- hydrolysis using the enzymes endogenous of said yeast cells, optionally with the addition of exogenous proteases to yeast cells, such as, for example, papain.
- the hydrolysis is carried out at 50 ° C. for 24 hours, so as to solubilize at least 60% by mass of the solids of the yeast cells.
- the enzymatic autolyses or hydrolyses according to the invention are carried out between 45 ° C. and 55 ° C. for 18 to 36 hours, without the use of any enzyme that can solubilize glucans or mannoproteins.
- the solubilized fraction is separated from the insoluble fraction by several successive centrifugation and washing steps with water.
- the insoluble fraction is dried on drums heated to a solids content of 95% by weight.
- the agglomerates formed are removed by sieving and yeast peels according to the invention are obtained.
- yeast peels devoid of mannan The yeast peels obtained above are suspended in water and heated in an alkaline medium between 70 ° C. and 100 ° C. for not more than three hours. In particular, the suspension in a sodium alkaline aqueous medium is heated at 85 ° C. for two hours.
- the fraction solubilized by this treatment is removed, the remaining non-solubilized fraction being recovered, washed and generally dried.
- the solubilized fraction containing mannoproteins and also glycogen is removed by centrifugation and washing.
- the yeast peels obtained after the hot alkaline treatment are preferably subjected to an acid treatment in order to remove any trace of mannoproteins.
- the insoluble fraction is thus acidified with phosphoric or acetic acid, and then incubated at 80 ° C. for one to two hours.
- the solubilized fraction containing the residues of mannoproteins, glycogen and also some lipids is removed by centrifugation and washing.
- the mixture is then brought to a pH of 5.2 by adding 0.3ml of 1M acetic acid and 1.2ml of 0.2M sodium acetate and mixing the ingredients. Distilled water is added to a total volume of 2 ml. 0.5 ml of the suspension thus obtained are incubated for 15 hours in the presence of an excess of Aspergillus niger amyloglucosidase, such as sold by ROCHE under the name Cat. No. 102,857, at 55 ° C. After centrifugation, the glucose released is assayed by enzymatic assay.
- the enzymatic determination of glucose is described in particular in the manual "Methods of Biochemical Analysis and Food Analysis - using Single Reagents", published by BOEHRINGER MANNHEIM GmbH Biochemica, ⁇ 1989, pages 50 to 55, and is preferably produced using the "Test -Combination D-Glucose / - Fructose ", Cat. No. 139 106 of the subsidiary of ROCHE: BOEHRINGER MANNHEIM GmbH / R-BIOPHARM GmbH in Darmstadt, Germany.
- the quantity (in mg) of glucose thus measured corresponds to the amount of glycogen present in the sample expressed in equivalent weight of glucose.
- This difference (in mg) between the two amounts of glucose assayed corresponds to the total amount of glucans present in the sample, this quantity being expressed in equivalent weight of glucose.
- the quantity (in mg) of metered mannose corresponds to the total amount of mannan present in the sample, this quantity being expressed in equivalent mannose mass.
- the yeast peels thus obtained have a solids content of 95% by weight.
- composition of yeast barks containing mannans and mannan-free yeasts (obtained by hot alkaline treatment) is given in Table 1.
- Table 1 Composition of Yeast Bark According to the Invention
- glycogen content was less than 10% by mass on solids.
- Example 2 Effect of Yeast Bark According to the Invention on the Insulin Concentration of Non-diabetic Overweight Subjects and Non-Insulin Dependent Diabetic Subjects (NIDDM)
- yeast peels yeast peels devoid of mannan
- yeast peels devoid of mannan yeast peels devoid of mannan
- the inclusion criteria are: a body mass index between 25 and 30 kg / m 2 (limits included), age between 30 and 65 years (limits included), normal fasting glucose ⁇ 7 mmol / l, HbAlc ⁇ 6%, total cholesterol ⁇ 7.0 mmol / l, triglycerides ⁇ 4.0 mmol / l.
- the inclusion criteria are: age between 30 and 65 years (limits included), treatment with metformin and / or sulfonylureas and / or glinides and / or glitazones for at least 3 months, HbAIc ⁇ 10%, total cholesterol ⁇ 7.0 mmol / l, triglycerides ⁇ 4.0 mmol / l.
- the main exclusion criteria are: type 1 diabetes, type 2 diabetes treated with insulin or acarbose, insulinopenia, chronic renal or hepatic insufficiency, history of chronic gastrointestinal disease, endocrine pathology, treatment that may interfere with the metabolism of carbohydrates and eating behavior, intolerance to cow's milk, claustrophobia (calorimetric measurements under Canopy®), pregnant women, subjects who are heavy consumers of products contained in the list of foods to be banned.
- OGTT Oral Hyperglycemia Tests
- 8g of yeast peels and 9g of beta-glucans are used in OGTT tests. It should be noted that the consumption of yeast bark at the expected dose of 8 g does not exceed the consumption levels observed for baking yeasts and yeast-foods.
- the products are diluted in 167 ml of a solution of 13 to 30% Cglucose containing 50g of 13 Cglucose.
- the 167 ml of 13 Cglucose solution will be supplemented with 28 ml of whole milk and 50 ml of semi-skimmed milk to obtain an energy equivalent to 8 g of yeast peel and 9 g of betaglucans.
- the metabolic day is divided into two parts: a basal period (T-120 to TO) during which the basal conditions (fasting) are measured, then the postprandial period of 4h45 (T15 - T300) consecutive to the OGTT.
- the patient ingests 50 g of 13 Cglucose TO. Depending on the draw, it is optionally added extemporaneously to the solution either yeast peel, betaglucan or milk. The solution should be ingested in less than 10 minutes. The patient must remain in supine position for the next 5 hours, avoiding sleep. During the day of exploration, the subject can consume water (300ml) maximum. Plasma insulin concentrations are determined in basal (between
- T-120 and TO in the postprandial period from T15 to T300.
- the venous samples are immediately centrifuged and the plasma recovered for the insulin dosage. Plasma insulin is assayed by radioimmunoassay (Medgenix Diagnostics®, Rungis, France).
- results are presented in average group form +/- standard deviation to mean (ESM).
- the results obtained with the 3 conditions are compared in pairs using the non-parametric Wilcoxon test on paired series.
- the Statview software (Statview, Abacus Concepts, Berkeley, CA) is used.
- yeast bark a trend towards a decrease in insulin peak and area under curve is observed compared to placebo.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008801002666A CN101801400B (zh) | 2007-07-25 | 2008-07-25 | 酵母片用于治疗和/或预防高胰岛素血症的用途 |
CA2696462A CA2696462C (fr) | 2007-07-25 | 2008-07-25 | Utilisation d'ecorces de levure pour le traitement et / ou la prevention de l'hyperinsulinemie |
SI200831660A SI2170359T1 (sl) | 2007-07-25 | 2008-07-25 | Uporaba kvasnih kosmičev pri zdravljenju in/ali preprečevanju hiperinzulinemije |
AU2008278975A AU2008278975B2 (en) | 2007-07-25 | 2008-07-25 | Use of yeast cell walls for the treatment and/or prevention of hyperinsulinaemia |
ES08786472.4T ES2586244T3 (es) | 2007-07-25 | 2008-07-25 | Utilización de cortezas de levadura para el tratamiento y/o la prevención de la hiperinsulinemia |
US12/670,436 US9750762B2 (en) | 2007-07-25 | 2008-07-25 | Use of yeast flakes for treating and/or preventing hyperinsulinemia |
EP08786472.4A EP2170359B1 (fr) | 2007-07-25 | 2008-07-25 | Utilisation d'écorces de levure pour le traitement et / ou la prévention de l'hyperinsulinémie |
JP2010517414A JP5530354B2 (ja) | 2007-07-25 | 2008-07-25 | 高インスリン血症の治療および/または予防のための酵母細胞壁の使用 |
NO20100268A NO342072B1 (no) | 2007-07-25 | 2010-02-23 | Anvendelse av gjærcellevegger til behandling og/eller forebygging av hyperinsulinemi |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0756731 | 2007-07-25 | ||
FR0756731A FR2919187B1 (fr) | 2007-07-25 | 2007-07-25 | Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009013357A1 true WO2009013357A1 (fr) | 2009-01-29 |
Family
ID=39271450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/059815 WO2009013357A1 (fr) | 2007-07-25 | 2008-07-25 | Utilisation d'écorces de levure pour le traitement et / ou la prévention de l'hyperinsulinémie |
Country Status (16)
Country | Link |
---|---|
US (1) | US9750762B2 (fr) |
EP (1) | EP2170359B1 (fr) |
JP (1) | JP5530354B2 (fr) |
KR (1) | KR101593705B1 (fr) |
CN (1) | CN101801400B (fr) |
AU (1) | AU2008278975B2 (fr) |
CA (1) | CA2696462C (fr) |
ES (1) | ES2586244T3 (fr) |
FR (1) | FR2919187B1 (fr) |
NO (1) | NO342072B1 (fr) |
PL (1) | PL2170359T3 (fr) |
RU (1) | RU2463065C2 (fr) |
SG (1) | SG169346A1 (fr) |
SI (1) | SI2170359T1 (fr) |
WO (1) | WO2009013357A1 (fr) |
ZA (1) | ZA201000381B (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011018580A1 (fr) | 2009-08-14 | 2011-02-17 | Lesaffre Et Compagnie | Compositions a base de chrome et de beta-glucanes de levure destinees a la prevention et/ou au traitement du diabete |
WO2013021138A2 (fr) * | 2011-08-09 | 2013-02-14 | Lesaffre Et Compagnie | Ecorces de levure enrichies en vitamine d2, compositions les contenant, leur procede de preparation, leurs utilisations et dispositif permettant la mise en oeuvre du procede |
EP3685681A1 (fr) | 2019-01-23 | 2020-07-29 | Lesaffre et Compagnie | Produit de levure et composition le comprenant, pour utilisation comme agent prébiotique |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2870969A1 (fr) * | 2013-11-08 | 2015-05-13 | Biocodex | Composition pharmaceutique pour la réduction de la masse adipeuse |
CN107233298B (zh) * | 2016-03-28 | 2021-01-22 | 复旦大学 | 一种促进蛋白多肽药物口服吸收的酵母细胞壁微粒制剂 |
EP3761995A1 (fr) * | 2018-03-08 | 2021-01-13 | DSM IP Assets B.V. | Bêta-glucanes de levure |
WO2023175153A1 (fr) | 2022-03-18 | 2023-09-21 | Fumi Ingredients B.V. | Extrait de cellules microbiennes, procédé d'obtention dudit extrait de cellules microbiennes et utilisation dudit extrait de cellules microbiennes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61167622A (ja) * | 1985-01-22 | 1986-07-29 | Asahi Breweries Ltd | 糖尿病コントロ−ル剤 |
EP1094117A1 (fr) * | 1999-10-22 | 2001-04-25 | LESAFFRE et Cie | Poudre de mannoprotéines soluble |
FR2825004A1 (fr) * | 2001-05-22 | 2002-11-29 | Bio Springer | Produit dietetique satiant |
WO2005021015A1 (fr) * | 2003-08-11 | 2005-03-10 | Lesaffre Et Compagnie | Ecorces de levures pour le traitement ou la prevention de l’hyperglycemie ou pour la stabilisation de la glycemie |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2756907B2 (ja) * | 1993-12-28 | 1998-05-25 | 日本製紙株式会社 | 酵母エキス組成物及びその製造法並びにそれを含有する飼料 |
UA85561C2 (ru) * | 2003-08-11 | 2009-02-10 | Лезаффр Э Компани | Применение клеточных стенок дрожжей для лечения или профилактики гипергликемии или для стабилизации содержания сахара в крови |
JP4302684B2 (ja) * | 2005-06-30 | 2009-07-29 | 株式会社 ミヤトウ野草研究所 | コタラヒンブツ葉エキスを含有した健康食品の製造方法 |
-
2007
- 2007-07-25 FR FR0756731A patent/FR2919187B1/fr active Active
-
2008
- 2008-07-25 SG SG201100526-1A patent/SG169346A1/en unknown
- 2008-07-25 JP JP2010517414A patent/JP5530354B2/ja not_active Expired - Fee Related
- 2008-07-25 EP EP08786472.4A patent/EP2170359B1/fr active Active
- 2008-07-25 CA CA2696462A patent/CA2696462C/fr active Active
- 2008-07-25 WO PCT/EP2008/059815 patent/WO2009013357A1/fr active Application Filing
- 2008-07-25 US US12/670,436 patent/US9750762B2/en active Active
- 2008-07-25 PL PL08786472.4T patent/PL2170359T3/pl unknown
- 2008-07-25 AU AU2008278975A patent/AU2008278975B2/en not_active Ceased
- 2008-07-25 KR KR1020107004078A patent/KR101593705B1/ko active IP Right Grant
- 2008-07-25 CN CN2008801002666A patent/CN101801400B/zh active Active
- 2008-07-25 ES ES08786472.4T patent/ES2586244T3/es active Active
- 2008-07-25 RU RU2010104981/15A patent/RU2463065C2/ru not_active IP Right Cessation
- 2008-07-25 SI SI200831660A patent/SI2170359T1/sl unknown
-
2010
- 2010-01-19 ZA ZA201000381A patent/ZA201000381B/xx unknown
- 2010-02-23 NO NO20100268A patent/NO342072B1/no not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61167622A (ja) * | 1985-01-22 | 1986-07-29 | Asahi Breweries Ltd | 糖尿病コントロ−ル剤 |
EP1094117A1 (fr) * | 1999-10-22 | 2001-04-25 | LESAFFRE et Cie | Poudre de mannoprotéines soluble |
FR2825004A1 (fr) * | 2001-05-22 | 2002-11-29 | Bio Springer | Produit dietetique satiant |
WO2005021015A1 (fr) * | 2003-08-11 | 2005-03-10 | Lesaffre Et Compagnie | Ecorces de levures pour le traitement ou la prevention de l’hyperglycemie ou pour la stabilisation de la glycemie |
Non-Patent Citations (7)
Title |
---|
"GLUCAGEL TM. Barley bata-glucan and healthy blood glucose", INTERNET PUBLICATION, pages 1 - 3, XP002476552, Retrieved from the Internet <URL:www.glucagel.com/bloodglucose.pdf> * |
CANTERBURY & NELSON NUTRACEUTICALS : NEW ZEALAND /GRACELINC LTD.: "GLUCAGEL", - 2002, INTERNET PUBLICATION, pages 1 - 2, XP002476551, Retrieved from the Internet <URL:http://www.nutraceuticals.org.nz/index.cfm/Member%20Profiles/Gracelinc%20Ltd> * |
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; November 2005 (2005-11-01), BIORKLUND M ET AL: "Changes in serum lipids and postprandial glucose and insulin concentrations after consumption of beverages with [beta]-glucans from oats or barley: A randomised dose-controlled trial", XP002476553, Database accession no. EMB-2005525568 * |
DATABASE WPI Week 198636, Derwent World Patents Index; AN 1986-236776, XP002476554 * |
EUROPEAN JOURNAL OF CLINICAL NUTRITION 200511 GB, vol. 59, no. 11, November 2005 (2005-11-01), pages 1272 - 1281, ISSN: 0954-3007 1476-5640 * |
JENKINS A L ET AL: "Depression of the glycemic index by high levels of [beta]-glucan fiber in two functional foods tested in type 2 diabetes", EUROPEAN JOURNAL OF CLINICAL NUTRITION 2002 GB, vol. 56, no. 7, 2002, pages 622 - 628, XP002476550, ISSN: 0954-3007 * |
KIM YEA-WOON ET AL: "Anti-diabetic activity of beta-glucans and their enzymatically hydrolyzed oligosaccharides from Agaricus blazei", BIOTECHNOLOGY LETTERS, vol. 27, no. 7, April 2005 (2005-04-01), pages 483 - 487, XP002476549, ISSN: 0141-5492 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011018580A1 (fr) | 2009-08-14 | 2011-02-17 | Lesaffre Et Compagnie | Compositions a base de chrome et de beta-glucanes de levure destinees a la prevention et/ou au traitement du diabete |
FR2949064A1 (fr) * | 2009-08-14 | 2011-02-18 | Lesaffre & Cie | Nouvelles compositions destinees a la prevention et/ou au traitement du diabete |
WO2013021138A2 (fr) * | 2011-08-09 | 2013-02-14 | Lesaffre Et Compagnie | Ecorces de levure enrichies en vitamine d2, compositions les contenant, leur procede de preparation, leurs utilisations et dispositif permettant la mise en oeuvre du procede |
FR2978967A1 (fr) * | 2011-08-09 | 2013-02-15 | Lesaffre & Cie | Ecorces de levure enrichies en vitamine d2, compositions les contenant, leur procede de preparation, leurs utilisations et dispositif permettant la mise en oeuvre du procede |
WO2013021138A3 (fr) * | 2011-08-09 | 2014-03-20 | Lesaffre Et Compagnie | Ecorces de levure enrichies en vitamine d2, compositions les contenant, leur procede de preparation, leurs utilisations et dispositif permettant la mise en oeuvre du procede |
EP3685681A1 (fr) | 2019-01-23 | 2020-07-29 | Lesaffre et Compagnie | Produit de levure et composition le comprenant, pour utilisation comme agent prébiotique |
WO2020152229A1 (fr) | 2019-01-23 | 2020-07-30 | Lesaffre Et Compagnie | Produit de levure, et composition le comprenant, s'utilisant comme agent prébiotique |
Also Published As
Publication number | Publication date |
---|---|
CN101801400A (zh) | 2010-08-11 |
ZA201000381B (en) | 2010-10-27 |
US9750762B2 (en) | 2017-09-05 |
US20100196413A1 (en) | 2010-08-05 |
EP2170359A1 (fr) | 2010-04-07 |
FR2919187B1 (fr) | 2009-11-27 |
AU2008278975A1 (en) | 2009-01-29 |
RU2010104981A (ru) | 2011-08-27 |
KR101593705B1 (ko) | 2016-02-12 |
CA2696462A1 (fr) | 2009-01-29 |
SG169346A1 (en) | 2011-03-30 |
NO342072B1 (no) | 2018-03-19 |
NO20100268L (no) | 2010-02-23 |
EP2170359B1 (fr) | 2016-05-11 |
AU2008278975B2 (en) | 2013-09-19 |
JP5530354B2 (ja) | 2014-06-25 |
RU2463065C2 (ru) | 2012-10-10 |
CA2696462C (fr) | 2016-08-23 |
KR20100063039A (ko) | 2010-06-10 |
SI2170359T1 (sl) | 2016-10-28 |
ES2586244T3 (es) | 2016-10-13 |
PL2170359T3 (pl) | 2016-11-30 |
FR2919187A1 (fr) | 2009-01-30 |
JP2010534223A (ja) | 2010-11-04 |
CN101801400B (zh) | 2013-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2170359B1 (fr) | Utilisation d'écorces de levure pour le traitement et / ou la prévention de l'hyperinsulinémie | |
US20090022758A1 (en) | Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilization of glycemia | |
EP2010200B1 (fr) | Utilisation de polysaccharides d'origine fongique comme composition pharmaceutique ou complements alimentaires | |
EP3423072B1 (fr) | Compositions pour le traitement des candidoses | |
EP2701710A1 (fr) | Composition anti-inflammatoire de l'intestin comprenant du maltitol | |
CN100377719C (zh) | 用于治疗或预防高血糖症或用于稳定血糖的酵母细胞壁 | |
EP4308138A1 (fr) | Inhibiteurs glycosidiques de levure | |
WO2011018580A1 (fr) | Compositions a base de chrome et de beta-glucanes de levure destinees a la prevention et/ou au traitement du diabete | |
FR3078610A1 (fr) | Composition de probiotiques particuliers et utilisation pour diminuer les symptomes inflammatoires digestifs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880100266.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08786472 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008278975 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2696462 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010517414 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12670436 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008786472 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008278975 Country of ref document: AU Date of ref document: 20080725 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1180/DELNP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20107004078 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010104981 Country of ref document: RU |